Aryan Naghedi, Hamidreza Varastehravan, Hasan Haghaninejad, Arvin Naghedi, Nima Farshadi
Cardiovascular diseases are among important causes of death. Atherosclerosis is an important etiology for coronary artery diseases in which coronary artery calcification plays a principal role. Recently novel cardiovascular risk factors in coronary calcification are under attention. In this study, we investigated possible association between novel cardiovascular risk factors and coronary calcification. This is a prospectively registered systematic review and meta-analysis in PROSPERO and was performed in accordance with PRISMA guidelines. Medical databases were searched. Primary papers were screened and studies reporting our outcomes of interest were selected for data extraction. Quantitative data syntheses were performed using Comprehensive Meta-analysis Ver.3. In this study, 5252 papers were screened and finally 28 papers including 31241 patients underwent data extraction. Based on our findings, neutrophil/lymphocyte ratio (8 out of 10), red cell distribution width (r = 0.250, p < 0.0001), and interleukin 6 (odds ratio [OR]: 1.101 [95% confidence interval (CI): 1.001-1.210], p = 0.047) were associated with severity of coronary calcification while C-reactive protein (one out of eight) was not associated with coronary calcification. Results of lymphocyte/monocyte ratio (r = -0.120, p < 0.001), platelet/lymphocyte ratio (OR: 1.47 [95% CI: 0.89-2.41, p = 0.124]), and MPV (r = 0.017, p = 0.814 vs. OR: 1.91 [95% CI: 1.28-2.85, p = 0.002]) remained controversial due to few number of included studies or contrary results. We can conclude that neutrophil/lymphocyte ratio, red cell distribution width, and interleukin-6 are significantly associated with coronary calcification and C-reactive protein is not significantly associated with severity of coronary calcification. Our results about mean platelet volume, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio are not reliable and require further investigations.
心血管疾病是导致死亡的重要原因之一。动脉粥样硬化是冠状动脉疾病的重要病因,冠状动脉钙化在其中起主要作用。近年来,冠状动脉钙化的新型心血管危险因素引起了人们的关注。在这项研究中,我们调查了新型心血管危险因素与冠状动脉钙化之间的可能关联。这是一项普洛斯彼罗前瞻性注册的系统评价和荟萃分析,并按照PRISMA指南进行。检索了医学数据库。筛选主要论文,并选择报告我们感兴趣的结果的研究进行数据提取。采用综合meta分析Ver.3进行定量数据综合。本研究共筛选了5252篇论文,最终进行了28篇论文31241例患者的数据提取。根据我们的研究结果,中性粒细胞/淋巴细胞比率(8 / 10)、红细胞分布宽度(r = 0.250, p < 0.0001)和白细胞介素6(比值比[OR]: 1.101[95%可信区间(CI): 1.001-1.210], p = 0.047)与冠状动脉钙化的严重程度相关,而c反应蛋白(1 / 8)与冠状动脉钙化无关。淋巴细胞/单核细胞比率(r = -0.120, p < 0.001)、血小板/淋巴细胞比率(OR: 1.47 [95% CI: 0.89-2.41, p = 0.124])和MPV (r = 0.017, p = 0.814 vs. OR: 1.91 [95% CI: 1.28-2.85, p = 0.002])的结果由于纳入的研究较少或相反的结果仍然存在争议。我们可以得出结论,中性粒细胞/淋巴细胞比值、红细胞分布宽度和白细胞介素-6与冠状动脉钙化显著相关,而c反应蛋白与冠状动脉钙化严重程度无显著相关性。我们关于平均血小板体积、血小板/淋巴细胞比率和淋巴细胞/单核细胞比率的结果不可靠,需要进一步研究。
{"title":"Importance of so called \"novel cardiovascular risk factors\" in severity of coronary artery calcification; how serious they should be taken: a systematic review and metaanalysis.","authors":"Aryan Naghedi, Hamidreza Varastehravan, Hasan Haghaninejad, Arvin Naghedi, Nima Farshadi","doi":"10.24875/ACM.210004061","DOIUrl":"https://doi.org/10.24875/ACM.210004061","url":null,"abstract":"<p><p>Cardiovascular diseases are among important causes of death. Atherosclerosis is an important etiology for coronary artery diseases in which coronary artery calcification plays a principal role. Recently novel cardiovascular risk factors in coronary calcification are under attention. In this study, we investigated possible association between novel cardiovascular risk factors and coronary calcification. This is a prospectively registered systematic review and meta-analysis in PROSPERO and was performed in accordance with PRISMA guidelines. Medical databases were searched. Primary papers were screened and studies reporting our outcomes of interest were selected for data extraction. Quantitative data syntheses were performed using Comprehensive Meta-analysis Ver.3. In this study, 5252 papers were screened and finally 28 papers including 31241 patients underwent data extraction. Based on our findings, neutrophil/lymphocyte ratio (8 out of 10), red cell distribution width (r = 0.250, p < 0.0001), and interleukin 6 (odds ratio [OR]: 1.101 [95% confidence interval (CI): 1.001-1.210], p = 0.047) were associated with severity of coronary calcification while C-reactive protein (one out of eight) was not associated with coronary calcification. Results of lymphocyte/monocyte ratio (r = -0.120, p < 0.001), platelet/lymphocyte ratio (OR: 1.47 [95% CI: 0.89-2.41, p = 0.124]), and MPV (r = 0.017, p = 0.814 vs. OR: 1.91 [95% CI: 1.28-2.85, p = 0.002]) remained controversial due to few number of included studies or contrary results. We can conclude that neutrophil/lymphocyte ratio, red cell distribution width, and interleukin-6 are significantly associated with coronary calcification and C-reactive protein is not significantly associated with severity of coronary calcification. Our results about mean platelet volume, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio are not reliable and require further investigations.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 2","pages":"212-222"},"PeriodicalIF":0.5,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/c0/7567AX222-ACM-93-212.PMC10161817.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Analia G Paolucci, Dhruv Krishnan, Mario B Principato, María A Von-Wulffen, Justo Carbajales, Adrian Baranchuk
*Correspondence: Justo Carbajales E-mail: cardiogenomica@gmail.com Available online: 04-04-2023 Arch Cardiol Mex. 2023;93(2):260-262 www.archivoscardiologia.com Date of reception: 21-05-2021 Date of acceptance: 26-05-2022 DOI: 10.24875/ACM.21000163 Chagas’ disease, caused by the parasite Trypanosoma cruzi, is one of the most pervasive endemic infections in Latin America, currently affecting approximately 7 million people1. Nearly 40% of patients eventually develop chronic Chagas’ cardiomyopathy (CCC), which can manifest with conduction disorders, arrhythmias, congestive heart failure, stroke, and/or sudden death1. After the initial acute phase of the disease, hosts who are incompletely treated with anti-parasitic agents enter the indeterminate phase, characterized by low levels of parasitemia and the absence of signs or symptoms. Nearly two-thirds of people in the indeterminate phase remain in this state for over 10 years. Unfortunately, the other third progress to the chronic stage, wherein patients again experience the effects of antigenic stimulation. Chronic Chagas’ disease most commonly presents as a slowly evolving inflammatory cardiomyopathy. The presence of high levels of inflammatory mediators in patients with Chagas’ disease suggests that the host’s immune response to parasitic activity could play a key role in the perpetuation of myocardial inflammation. Patients with CCC have been found to produce anti-β1 and -ß2 adrenergic autoantibodies and anti-M2 cholinergic autoantibodies in the heart2,3, through a phenomenon known molecular mimicry. The relationship between autoantibody titers and the degree of cardiac disease remains controversial. The aim of this study was to evaluate whether patients with CCC and higher levels of anti-β1 autoantibodies had a significantly higher presence of cardiac arrhythmias or conduction disorders, which are considered clinical markers of CCC. Ethics clearance was granted by the bioethics commission of Jorge Ramos Mejía Hospital in Buenos Aires, Argentina. The study population consisted of 65 patients with at least a 20-year history of positive serology for Chagas’ disease to allow adequate time for manifestations of CCC to develop (Table 1). All patients had a left ventricular ejection fraction (LVEF) of either less than or equal to 35% or greater than or equal to 50%, as evaluated by Doppler echocardiography, to eliminate subjective differences in echocardiographic data. Patients with LVEF between 36% and 49%, or who had another established cause of cardiomyopathy, were excluded from the study. The presence of arrhythmias and conduction disorders was evaluated using electrocardiograms (ECG), storage data from implantable cardioverter-defibrillators (ICD) and pacemaker interrogation, and 24-h Holter
{"title":"[Lack of correlation for anti-β1 autoantibodies and cardioelectric disorders in chagas cardiomyopathy].","authors":"Analia G Paolucci, Dhruv Krishnan, Mario B Principato, María A Von-Wulffen, Justo Carbajales, Adrian Baranchuk","doi":"10.24875/ACM.21000163","DOIUrl":"https://doi.org/10.24875/ACM.21000163","url":null,"abstract":"*Correspondence: Justo Carbajales E-mail: cardiogenomica@gmail.com Available online: 04-04-2023 Arch Cardiol Mex. 2023;93(2):260-262 www.archivoscardiologia.com Date of reception: 21-05-2021 Date of acceptance: 26-05-2022 DOI: 10.24875/ACM.21000163 Chagas’ disease, caused by the parasite Trypanosoma cruzi, is one of the most pervasive endemic infections in Latin America, currently affecting approximately 7 million people1. Nearly 40% of patients eventually develop chronic Chagas’ cardiomyopathy (CCC), which can manifest with conduction disorders, arrhythmias, congestive heart failure, stroke, and/or sudden death1. After the initial acute phase of the disease, hosts who are incompletely treated with anti-parasitic agents enter the indeterminate phase, characterized by low levels of parasitemia and the absence of signs or symptoms. Nearly two-thirds of people in the indeterminate phase remain in this state for over 10 years. Unfortunately, the other third progress to the chronic stage, wherein patients again experience the effects of antigenic stimulation. Chronic Chagas’ disease most commonly presents as a slowly evolving inflammatory cardiomyopathy. The presence of high levels of inflammatory mediators in patients with Chagas’ disease suggests that the host’s immune response to parasitic activity could play a key role in the perpetuation of myocardial inflammation. Patients with CCC have been found to produce anti-β1 and -ß2 adrenergic autoantibodies and anti-M2 cholinergic autoantibodies in the heart2,3, through a phenomenon known molecular mimicry. The relationship between autoantibody titers and the degree of cardiac disease remains controversial. The aim of this study was to evaluate whether patients with CCC and higher levels of anti-β1 autoantibodies had a significantly higher presence of cardiac arrhythmias or conduction disorders, which are considered clinical markers of CCC. Ethics clearance was granted by the bioethics commission of Jorge Ramos Mejía Hospital in Buenos Aires, Argentina. The study population consisted of 65 patients with at least a 20-year history of positive serology for Chagas’ disease to allow adequate time for manifestations of CCC to develop (Table 1). All patients had a left ventricular ejection fraction (LVEF) of either less than or equal to 35% or greater than or equal to 50%, as evaluated by Doppler echocardiography, to eliminate subjective differences in echocardiographic data. Patients with LVEF between 36% and 49%, or who had another established cause of cardiomyopathy, were excluded from the study. The presence of arrhythmias and conduction disorders was evaluated using electrocardiograms (ECG), storage data from implantable cardioverter-defibrillators (ICD) and pacemaker interrogation, and 24-h Holter","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 2","pages":"260-262"},"PeriodicalIF":0.5,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/d1/7567AX222-ACM-93-260.PMC10161807.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9414453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olga De La Ossa-Mercado, Francisco De La Hoz-Bequis, Heidy Marsiglia-Armella, Andrea Zárate-Vergara, Irina Tirado-Pérez
Objective: To evaluate the capacity of red cell distribution width (RDW) to predict mortality in children undergoing cardiovascular surgery at the Fundación Hospital Infantil Napoleón Franco Pareja, in Colombia.
Method: Retrospective cross-sectional analytical study that included 45 individuals aged 0 to 17 years operated for congenital heart disease. The RACHS-1 (Risk Adjustment in Congenital Heart Surgery) scale and laboratory variables including the RDW were applied. The association between RDW and mortality was determined by ROC curve analysis and Spearman’s rho correlation.
Results: An RDW greater than 15.52% represented 1.6 times more risk, compared to individuals below that value (95% confidence interval: 1.01-2.6; p = 0.034). The RDW values did not correlate with days of hospital stay or complications. The preoperative RDW and RACHS-1 score were significantly higher in the mortality group. The relationship between presurgical RDW and the RACHS-1 score was significant.
Conclusions: In our study, the preoperative RDW had moderate power to discriminate perioperative mortality in the surgical correction of congenital heart disease. More studies with a larger sample size are required.
{"title":"[Red cell distribution width in the prognosis of surgical correction of congenital heart diseases].","authors":"Olga De La Ossa-Mercado, Francisco De La Hoz-Bequis, Heidy Marsiglia-Armella, Andrea Zárate-Vergara, Irina Tirado-Pérez","doi":"10.24875/ACM.210003401","DOIUrl":"https://doi.org/10.24875/ACM.210003401","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the capacity of red cell distribution width (RDW) to predict mortality in children undergoing cardiovascular surgery at the Fundación Hospital Infantil Napoleón Franco Pareja, in Colombia.</p><p><strong>Method: </strong>Retrospective cross-sectional analytical study that included 45 individuals aged 0 to 17 years operated for congenital heart disease. The RACHS-1 (Risk Adjustment in Congenital Heart Surgery) scale and laboratory variables including the RDW were applied. The association between RDW and mortality was determined by ROC curve analysis and Spearman’s rho correlation.</p><p><strong>Results: </strong>An RDW greater than 15.52% represented 1.6 times more risk, compared to individuals below that value (95% confidence interval: 1.01-2.6; p = 0.034). The RDW values did not correlate with days of hospital stay or complications. The preoperative RDW and RACHS-1 score were significantly higher in the mortality group. The relationship between presurgical RDW and the RACHS-1 score was significant.</p><p><strong>Conclusions: </strong>In our study, the preoperative RDW had moderate power to discriminate perioperative mortality in the surgical correction of congenital heart disease. More studies with a larger sample size are required.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 2","pages":"156-163"},"PeriodicalIF":0.5,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/6e/7567AX222-ACM-93-156.PMC10161812.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10256270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan C Plata-Corona, G Lisseth Hernández-González, Manuel A Candia-Ramírez, Jorge D Sierra-Lara, José O Arenas-Díaz
{"title":"[Nacimiento anómalo de arteria pulmonar derecha en un paciente joven con síndrome de eisenmenger].","authors":"Juan C Plata-Corona, G Lisseth Hernández-González, Manuel A Candia-Ramírez, Jorge D Sierra-Lara, José O Arenas-Díaz","doi":"10.24875/ACM.22000201","DOIUrl":"10.24875/ACM.22000201","url":null,"abstract":"","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":" ","pages":"507-510"},"PeriodicalIF":0.5,"publicationDate":"2023-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9289316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ramírez-Cedillo David, Ruch G Nuñez-Faña, Juan M Sterling-Aracena, Italo D Masini-Aguilera, Rocío A Peña-Juárez
{"title":"Perforación de la valva no coronariana en un paciente con síndrome de Laubry-Pezzi.","authors":"Ramírez-Cedillo David, Ruch G Nuñez-Faña, Juan M Sterling-Aracena, Italo D Masini-Aguilera, Rocío A Peña-Juárez","doi":"10.24875/ACM.21000224","DOIUrl":"https://doi.org/10.24875/ACM.21000224","url":null,"abstract":"","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 1","pages":"098-099"},"PeriodicalIF":0.5,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/f7/7567AX221-ACM-93-98.PMC10161845.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9782506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marc Roguera Sopena, Dolors Esteban Oliva, Marta Ocaña Rico, Wifredo Coroleu Lletget, Aneta M Zientalska Fendonczuk
*Correspondence: Marc Roguera Sopena E-mail: mroguera.germanstrias@gencat.cat Available online: 02-08-2022 Arch Cardiol Mex. 2023;93(1):124-126 www.archivoscardiologia.com Date of reception: 08-05-2022 Date of acceptance: 14-07-2022 DOI: 10.24875/ACM.22000146 Mother affected by autoimmune pluripathology and carrier of anti-Ro/SSA antibodies. She continues treatment with azathioprine during pregnancy. First well-controlled pregnancy with fetal diagnosis of suspected arrhythmia at 30 weeks of gestational age, without hemodynamic repercussion. It is oriented as atrial extrasystole and ultrasound controls are performed every 2 weeks, without objectifying changes. Gestation ends at 40 weeks by cesarean section given the difficulty in monitoring fetal well-being. Female neonate weighing 2720g (-1.6 SD), with normal umbilical artery pH (7.32) is born. However, she requires admission to the neonatal intensive care unit a few hours after birth due to bradycardia of 80 beats/min in continuous pulse oximetry. Electrocardiogram is monitored, presenting heart rates between 100 and 110 beats/min, a consequence of a first-degree atrioventricular block (PR interval of 160 ms), and periods of second-degree atrioventricular (AV) block, type Mobitz I (Wenckebach) with AV ratio of 4:3 (Fig. 1). No clinical or hemodynamic repercussion was observed. The following initial complementary tests are performed on the newborn: positive serological study for anti-Ro/ SSA; echocardiography-Doppler that rules out structural and functional heart disease; control electrocardiogram at 4 and 6 weeks of life without second-degree AV block, only first-degree persisting; Holter electrocardiogram study at 2 months of age with degree of AV conduction 1:1 in most of the recording; and occasional second Mobitz I AV block. There are no significant sinus node pauses. From hospital discharge, at 7 days of life, he presents a correct clinical evolution, without cardiovascular symptoms. In the electrocardiographic follow-up, up to 3 years of age, no recurrence of 2nd-degree AV block was detected. However, it maintains 1st-degree AV block with PR intervals of 160-180 ms. The physical and psychomotor development of the patient are completely normal. Serological control for anti-Ro/SSA at 1 year of age was made, with negative result.
{"title":"Transient type I 2<sup>nd</sup>-degree congenital atrioventricular block: A case report.","authors":"Marc Roguera Sopena, Dolors Esteban Oliva, Marta Ocaña Rico, Wifredo Coroleu Lletget, Aneta M Zientalska Fendonczuk","doi":"10.24875/ACM.22000146","DOIUrl":"https://doi.org/10.24875/ACM.22000146","url":null,"abstract":"*Correspondence: Marc Roguera Sopena E-mail: mroguera.germanstrias@gencat.cat Available online: 02-08-2022 Arch Cardiol Mex. 2023;93(1):124-126 www.archivoscardiologia.com Date of reception: 08-05-2022 Date of acceptance: 14-07-2022 DOI: 10.24875/ACM.22000146 Mother affected by autoimmune pluripathology and carrier of anti-Ro/SSA antibodies. She continues treatment with azathioprine during pregnancy. First well-controlled pregnancy with fetal diagnosis of suspected arrhythmia at 30 weeks of gestational age, without hemodynamic repercussion. It is oriented as atrial extrasystole and ultrasound controls are performed every 2 weeks, without objectifying changes. Gestation ends at 40 weeks by cesarean section given the difficulty in monitoring fetal well-being. Female neonate weighing 2720g (-1.6 SD), with normal umbilical artery pH (7.32) is born. However, she requires admission to the neonatal intensive care unit a few hours after birth due to bradycardia of 80 beats/min in continuous pulse oximetry. Electrocardiogram is monitored, presenting heart rates between 100 and 110 beats/min, a consequence of a first-degree atrioventricular block (PR interval of 160 ms), and periods of second-degree atrioventricular (AV) block, type Mobitz I (Wenckebach) with AV ratio of 4:3 (Fig. 1). No clinical or hemodynamic repercussion was observed. The following initial complementary tests are performed on the newborn: positive serological study for anti-Ro/ SSA; echocardiography-Doppler that rules out structural and functional heart disease; control electrocardiogram at 4 and 6 weeks of life without second-degree AV block, only first-degree persisting; Holter electrocardiogram study at 2 months of age with degree of AV conduction 1:1 in most of the recording; and occasional second Mobitz I AV block. There are no significant sinus node pauses. From hospital discharge, at 7 days of life, he presents a correct clinical evolution, without cardiovascular symptoms. In the electrocardiographic follow-up, up to 3 years of age, no recurrence of 2nd-degree AV block was detected. However, it maintains 1st-degree AV block with PR intervals of 160-180 ms. The physical and psychomotor development of the patient are completely normal. Serological control for anti-Ro/SSA at 1 year of age was made, with negative result.","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 1","pages":"124-126"},"PeriodicalIF":0.5,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/6a/7567AX221-ACM-93-124.PMC10161836.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Albina Aldomà-Balasch, Ma Isabel Hernández-Martín, Ma Dolors Viles-Bertran
A 17-years-old white male patient with no personal history of interest and asymptomatic from the cardiovascular point of view, but with a family history of paternal grandfather with dilated cardiomyopathy and mild depressed left ventricle ejection fraction (LVEF) who died at 83 years of age of a noncardiological cause. In an electrocardiogram (ECG) performed during a sports examination (field hockey player), T-wave inversion (TWI) was identified in the inferior leads (Fig. 1). For further evaluation, an echocardiogram was performed, showing a pattern of hypertrabeculation in the inferior, lateral, and apical walls of the left ventricular, which was confirmed by cardiac magnetic resonance imaging (Fig. 2A and 2B), fulfilling the criteria for noncompaction, with no other notable findings. As a result of these findings, the 57-year-old boy’s father, who was asymptomatic cardio-vascular and had a non-pathological ECG, was also evaluated and showed noncompaction cardiomyopathy with normal LVEF.
{"title":"T-wave inversion in young athletes: Normal or pathological?","authors":"Albina Aldomà-Balasch, Ma Isabel Hernández-Martín, Ma Dolors Viles-Bertran","doi":"10.24875/ACM.210003261","DOIUrl":"https://doi.org/10.24875/ACM.210003261","url":null,"abstract":"A 17-years-old white male patient with no personal history of interest and asymptomatic from the cardiovascular point of view, but with a family history of paternal grandfather with dilated cardiomyopathy and mild depressed left ventricle ejection fraction (LVEF) who died at 83 years of age of a noncardiological cause. In an electrocardiogram (ECG) performed during a sports examination (field hockey player), T-wave inversion (TWI) was identified in the inferior leads (Fig. 1). For further evaluation, an echocardiogram was performed, showing a pattern of hypertrabeculation in the inferior, lateral, and apical walls of the left ventricular, which was confirmed by cardiac magnetic resonance imaging (Fig. 2A and 2B), fulfilling the criteria for noncompaction, with no other notable findings. As a result of these findings, the 57-year-old boy’s father, who was asymptomatic cardio-vascular and had a non-pathological ECG, was also evaluated and showed noncompaction cardiomyopathy with normal LVEF.","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 1","pages":"096-097"},"PeriodicalIF":0.5,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/05/7567AX221-ACM-93-96.PMC10161837.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9415312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Enrique C Morales-Villegas, Carlos Yarleque, María L Almeida
Hypertension and dyslipidemia are key risk factors for cardiovascular disorders and mortality worldwide. To understand the local health system challenges faced in the management of the two conditions, a semi-systematic approach was adopted for quantifying stages of the journey of care of adult Mexican patients, namely, awareness, screening, diagnosis, treatment, adherence, and control. A structured literature search was conducted for articles published in English from 2010 to 2019 in EMBASE and MEDLINE databases. The articles restricted to patient subgroups, or not having national representativeness, thesis abstracts, letters to the editor, editorials, or case studies were excluded. In addition, an unstructured unrestricted literature search was conducted, on websites of Incidence and Prevalence Database, World Health Organization, Country's Ministry of Health, and Google. Last search was run on 28 August 2020 for Hypertension and 12 November 2019 for Dyslipidemia. Weighted or simple means were calculated for the pooled data. Seven articles of 647 retrievals for hypertension and 11 articles of 1265 retrievals for dyslipidemia were included in the review. The prevalence of hypertension was estimated to be 24.1%, while 59.9% of patients had awareness, 97.5% underwent screening, 18.4% had diagnosis, 50% received treatment, 50% were adherent to treatment, and 49.9% had disease control. Prevalence of dyslipidemia was estimated as 36.7%, while 8.6% of patients had awareness, 48.1% underwent screening, 28% had diagnosis, 68.9% received treatment, 50% were adherent to treatment, and 30% had disease control. The study suggested that addressing the synergistic effect of hypertension and dyslipidemia could reduce cardiovascular risk associated with these conditions.
{"title":"Management of hypertension and dyslipidemia in Mexico: Evidence, gaps, and approach.","authors":"Enrique C Morales-Villegas, Carlos Yarleque, María L Almeida","doi":"10.24875/ACM.21000330","DOIUrl":"https://doi.org/10.24875/ACM.21000330","url":null,"abstract":"<p><p>Hypertension and dyslipidemia are key risk factors for cardiovascular disorders and mortality worldwide. To understand the local health system challenges faced in the management of the two conditions, a semi-systematic approach was adopted for quantifying stages of the journey of care of adult Mexican patients, namely, awareness, screening, diagnosis, treatment, adherence, and control. A structured literature search was conducted for articles published in English from 2010 to 2019 in EMBASE and MEDLINE databases. The articles restricted to patient subgroups, or not having national representativeness, thesis abstracts, letters to the editor, editorials, or case studies were excluded. In addition, an unstructured unrestricted literature search was conducted, on websites of Incidence and Prevalence Database, World Health Organization, Country's Ministry of Health, and Google. Last search was run on 28 August 2020 for Hypertension and 12 November 2019 for Dyslipidemia. Weighted or simple means were calculated for the pooled data. Seven articles of 647 retrievals for hypertension and 11 articles of 1265 retrievals for dyslipidemia were included in the review. The prevalence of hypertension was estimated to be 24.1%, while 59.9% of patients had awareness, 97.5% underwent screening, 18.4% had diagnosis, 50% received treatment, 50% were adherent to treatment, and 49.9% had disease control. Prevalence of dyslipidemia was estimated as 36.7%, while 8.6% of patients had awareness, 48.1% underwent screening, 28% had diagnosis, 68.9% received treatment, 50% were adherent to treatment, and 30% had disease control. The study suggested that addressing the synergistic effect of hypertension and dyslipidemia could reduce cardiovascular risk associated with these conditions.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 1","pages":"077-087"},"PeriodicalIF":0.5,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/74/7567AX221-ACM-93-77.PMC10161831.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9422088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A Paola Yáñez-Guerrero, Diego Neac, Fernando León-Romero, Santiago Nava
Objective: To determine the efficacy and safety of temporary pacing with an active fixation lead placed trough the internal jugular vein and/or subclavian vein.
Methods: We analyzed a consecutive series of 25 out of 73 patients that had a pacemaker extraction and were pacing dependent requiring temporary pacing with an active fixation lead until the new pacemaker implant, from 2017 to 2021.
Results: After extraction 25 patients age 68 years ±16 years, required temporary pacing, the media for temporary pacing was 5 days. There were no mortality associated to temporary stimulation. Only one patient (4%) had a complication 4 days after the implant with capture fail due to a microdislogement requiring reintervention. Conclusion.
Conclusion: Temporary stimulation through active fixation pacemaker lead it is safe and effective.
{"title":"[Temporal stimulation by active fixation lead.]","authors":"A Paola Yáñez-Guerrero, Diego Neac, Fernando León-Romero, Santiago Nava","doi":"10.24875/ACM.210003071","DOIUrl":"https://doi.org/10.24875/ACM.210003071","url":null,"abstract":"<p><strong>Objective: </strong>To determine the efficacy and safety of temporary pacing with an active fixation lead placed trough the internal jugular vein and/or subclavian vein.</p><p><strong>Methods: </strong>We analyzed a consecutive series of 25 out of 73 patients that had a pacemaker extraction and were pacing dependent requiring temporary pacing with an active fixation lead until the new pacemaker implant, from 2017 to 2021.</p><p><strong>Results: </strong>After extraction 25 patients age 68 years ±16 years, required temporary pacing, the media for temporary pacing was 5 days. There were no mortality associated to temporary stimulation. Only one patient (4%) had a complication 4 days after the implant with capture fail due to a microdislogement requiring reintervention. Conclusion.</p><p><strong>Conclusion: </strong>Temporary stimulation through active fixation pacemaker lead it is safe and effective.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 1","pages":"022-025"},"PeriodicalIF":0.5,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/ce/7567AX221-ACM-93-22.PMC10161828.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9416210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heberto Aquino-Bruno, Juan F García-García, Roberto Muratalla-González, Marco A Alcántara-Meléndez, Julieta D Morales-Portano, Enrique B Gómez-Álvarez, José A Merino-Rajme, José A Castro-Rubio, Juan C Plata Corona
Objective: The purpose was to compare the outcomes of patients with ST-elevation myocardial infarction and multivessel coronary artery disease undergoing one-time multivessel revascularization (OTMVR) versus in-hospital staged complete revascularization with percutaneous coronary intervention.
Methods: This was a single-center, retrospective, observational, and cohort study, including data from January 2013 to April 2019. A total of 634 patients were included in the study. Comparisons were made between patients who underwent in-hospital staged complete revascularization versus OTMVR. The primary endpoint was all-cause in-hospital mortality, secondary endpoints included cardiovascular complications, all-cause new hospitalization, and mortality evaluated at 30 days and 1 year. In addition, we constructed a logistic regression model for determining the risk factors that predicted mortality.
Results: Of the 634 patients, 328 were treated with staged revascularization and 306 with OTMVR. About 76.7% were men, with a mean age of 63.3 years. Less complex coronary lesions and a higher proportion of the left anterior descending artery as the culprit vessel were found in the OTMVR group. Compared with staged revascularization, the primary and secondary endpoints occurred less frequently with OTMVR strategy.
Conclusions: OTMVR did not generate more complications and demonstrate better clinical outcomes than in-hospital staged revascularization.
{"title":"Complete revascularization with PCI in STEMI patients with multivessel disease, when is the appropriate time?","authors":"Heberto Aquino-Bruno, Juan F García-García, Roberto Muratalla-González, Marco A Alcántara-Meléndez, Julieta D Morales-Portano, Enrique B Gómez-Álvarez, José A Merino-Rajme, José A Castro-Rubio, Juan C Plata Corona","doi":"10.24875/ACM.21000375","DOIUrl":"https://doi.org/10.24875/ACM.21000375","url":null,"abstract":"<p><strong>Objective: </strong>The purpose was to compare the outcomes of patients with ST-elevation myocardial infarction and multivessel coronary artery disease undergoing one-time multivessel revascularization (OTMVR) versus in-hospital staged complete revascularization with percutaneous coronary intervention.</p><p><strong>Methods: </strong>This was a single-center, retrospective, observational, and cohort study, including data from January 2013 to April 2019. A total of 634 patients were included in the study. Comparisons were made between patients who underwent in-hospital staged complete revascularization versus OTMVR. The primary endpoint was all-cause in-hospital mortality, secondary endpoints included cardiovascular complications, all-cause new hospitalization, and mortality evaluated at 30 days and 1 year. In addition, we constructed a logistic regression model for determining the risk factors that predicted mortality.</p><p><strong>Results: </strong>Of the 634 patients, 328 were treated with staged revascularization and 306 with OTMVR. About 76.7% were men, with a mean age of 63.3 years. Less complex coronary lesions and a higher proportion of the left anterior descending artery as the culprit vessel were found in the OTMVR group. Compared with staged revascularization, the primary and secondary endpoints occurred less frequently with OTMVR strategy.</p><p><strong>Conclusions: </strong>OTMVR did not generate more complications and demonstrate better clinical outcomes than in-hospital staged revascularization.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 1","pages":"053-061"},"PeriodicalIF":0.5,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/f5/7567AX221-ACM-93-53.PMC10161824.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9413972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}